Research Article
Evaluation of lncRNA Expression Pattern and Potential Role in Heart Failure Pathology
Table 1
Clinical characteristics of the healthy control and HF patients.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; LDH: lactate dehydrogenase; CK: creatine kinase; CHO: cholesterol; TG: total triglyceride; LDL: low-density lipoprotein; HDL: high-density lipoprotein; ApoA: apolipoprotein A; ApoB: apolipoprotein B; NEFA: nonestesterified fatty acid; CKMB: creatine kinase MB; MYO: myoglobin; hsTNT: high sensitivity troponin T; NT-proBNP: N-terminal pro-B type natriuretic peptide; LVEF: left ventricular ejection fraction; LVFS: left ventricular fractional shortening; LVDd: left ventricular diameter at end-diastole. LVDs: left ventricular diameter at end-systole; IVST: interventricular septum thickness; LVPWd: left ventricular posterior wall diameter; ESV: end-systolic volume; EDV: end-diastolic volume; NYHA: New York Heart Association Class; HFrEF: HF with reduced EF; HFmrEF: HF with mildly reduced EF; HFpEF: HF with preserved EF. |